Search research articles
Contact Us
Filters
Showing results (171-180 of 192) with videos related to
Page
of 20
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
April 22, 2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells
Stavroula Baritaki, Eriko Suzuki, Kazuo Umezawa, et al.
Forum on Immunopathological Diseases and Therapeutics
|
November 29, 2013
Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma
Stavroula Baritaki, Sara Huerta-Yepez, Ma da Lourdas Cabrava-Haimandez, et al.
Cancer Biomarkers : Section a of Disease Markers
|
September 5, 2009
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome
Nam K Yoon, David B Seligson, David Chia, et al.
International Journal of Oncology
|
June 2, 2010
A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay
Haiming Chen, Cathy S Wang, Mingjie Li, et al.
Plos One
|
March 25, 2014
Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer
Saad Yousuf, MeiLi Duan, Erika L Moen, et al.
British Journal of Haematology
|
June 26, 2007
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
Richard A Campbell, Eric Sanchez, Jeffrey A Steinberg, et al.
BMC Cancer
|
October 18, 2015
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma
Gabriel G Vega, Alejandro Avilés-Salas, J Ramón Chalapud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions
Mario I Vega, Sara Huerta-Yepez, Melisa Martinez-Paniagua, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 6, 2006
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)
Lana Y Schumacher, Dan D Vo, Hermes J Garban, et al.
BMC Cancer
|
June 22, 2011
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival
Sara Huerta-Yepez, Nam K Yoon, Angeles Hernandez-Cueto, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 192) with videos related to
Sort By:
Page
of 20
Journal of Immunology (Baltimore, Md. : 1950)
|
April 22, 2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells
Stavroula Baritaki, Eriko Suzuki, Kazuo Umezawa, et al.
Forum on Immunopathological Diseases and Therapeutics
|
November 29, 2013
Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma
Stavroula Baritaki, Sara Huerta-Yepez, Ma da Lourdas Cabrava-Haimandez, et al.
Cancer Biomarkers : Section a of Disease Markers
|
September 5, 2009
Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome
Nam K Yoon, David B Seligson, David Chia, et al.
International Journal of Oncology
|
June 2, 2010
A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay
Haiming Chen, Cathy S Wang, Mingjie Li, et al.
Plos One
|
March 25, 2014
Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer
Saad Yousuf, MeiLi Duan, Erika L Moen, et al.
British Journal of Haematology
|
June 26, 2007
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
Richard A Campbell, Eric Sanchez, Jeffrey A Steinberg, et al.
BMC Cancer
|
October 18, 2015
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma
Gabriel G Vega, Alejandro Avilés-Salas, J Ramón Chalapud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2009
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions
Mario I Vega, Sara Huerta-Yepez, Melisa Martinez-Paniagua, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 6, 2006
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)
Lana Y Schumacher, Dan D Vo, Hermes J Garban, et al.
BMC Cancer
|
June 22, 2011
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival
Sara Huerta-Yepez, Nam K Yoon, Angeles Hernandez-Cueto, et al.
Page
of 20